The Biden Administration is waging a relentless regulatory assault on drug makers, typically under media radar. The most recent entrance could be the Health and Human Solutions Office’s new “price transparency” rule that seeks to dun drug makers to buy Medicaid. Soon after 4 decades, by some mutual settlement, the possession of the brand w